CN1053668C - 新型化合物及其制法和抗肿瘤剂 - Google Patents

新型化合物及其制法和抗肿瘤剂 Download PDF

Info

Publication number
CN1053668C
CN1053668C CN95194461A CN95194461A CN1053668C CN 1053668 C CN1053668 C CN 1053668C CN 95194461 A CN95194461 A CN 95194461A CN 95194461 A CN95194461 A CN 95194461A CN 1053668 C CN1053668 C CN 1053668C
Authority
CN
China
Prior art keywords
group
compound
formula
salt
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN95194461A
Other languages
English (en)
Chinese (zh)
Other versions
CN1158614A (zh
Inventor
富田恭司
千叶胜已
柏木茂树
柴森厚一郎
筑木保知
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Publication of CN1158614A publication Critical patent/CN1158614A/zh
Application granted granted Critical
Publication of CN1053668C publication Critical patent/CN1053668C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN95194461A 1994-06-14 1995-06-06 新型化合物及其制法和抗肿瘤剂 Expired - Lifetime CN1053668C (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
JP15657894 1994-06-14
JP156578/94 1994-06-14
JP156578/1994 1994-06-14
JP197921/94 1994-07-28
JP19792194 1994-07-28
JP197921/1994 1994-07-28
JP30691494 1994-11-15
JP306914/1994 1994-11-15
JP306914/94 1994-11-15
JP339956/1994 1994-12-28
JP33995694 1994-12-28
JP339956/94 1994-12-28
JP81705/1995 1995-03-13
JP81705/95 1995-03-13
JP8170595 1995-03-13

Publications (2)

Publication Number Publication Date
CN1158614A CN1158614A (zh) 1997-09-03
CN1053668C true CN1053668C (zh) 2000-06-21

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95194461A Expired - Lifetime CN1053668C (zh) 1994-06-14 1995-06-06 新型化合物及其制法和抗肿瘤剂

Country Status (27)

Country Link
US (1) US5817669A (enExample)
EP (1) EP0787726B1 (enExample)
JP (1) JP3391796B2 (enExample)
KR (1) KR100350921B1 (enExample)
CN (1) CN1053668C (enExample)
AT (1) ATE209645T1 (enExample)
AU (1) AU679859B2 (enExample)
BR (1) BR9508037A (enExample)
CA (1) CA2192824C (enExample)
CZ (1) CZ292631B6 (enExample)
DE (1) DE69524251T2 (enExample)
DK (1) DK0787726T3 (enExample)
ES (1) ES2163512T3 (enExample)
FI (1) FI112485B (enExample)
HK (1) HK1000495A1 (enExample)
HU (1) HU220072B (enExample)
MX (1) MX9606331A (enExample)
NO (1) NO307255B1 (enExample)
NZ (1) NZ287139A (enExample)
PL (1) PL181867B1 (enExample)
PT (1) PT787726E (enExample)
RO (1) RO117793B1 (enExample)
RU (1) RU2151770C1 (enExample)
SI (1) SI0787726T1 (enExample)
SK (1) SK281341B6 (enExample)
TW (1) TW319769B (enExample)
WO (1) WO1995034559A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677352B1 (en) * 2001-09-26 2004-01-13 Yamin Wang 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
WO2004091627A2 (en) * 2003-04-07 2004-10-28 Cylene Pharmaceuticals, Inc. Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
KR101077755B1 (ko) * 2003-09-10 2011-10-27 교린 세이야꾸 가부시키 가이샤 7-(4-치환-3-시클로프로필아미노메틸-1-피롤리디닐)퀴놀론카르본산 유도체
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
MX349188B (es) * 2004-03-15 2017-07-17 Sunesis Pharmaceuticals Inc Sns - 595 y metodos para utilizar el mismo.
RU2405782C2 (ru) * 2004-10-14 2010-12-10 Ф.Хоффманн-Ля Рош Аг Хиназолинилметилентиазолиноны в качестве cdk-1 ингибиторов
EP1805174A1 (en) * 2004-10-14 2007-07-11 F.Hoffmann-La Roche Ag 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity
US7563805B2 (en) * 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
US20070117770A1 (en) * 2005-08-19 2007-05-24 Cylene Pharmaceuticals, Inc. Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
JP5374153B2 (ja) * 2005-09-02 2013-12-25 サネシス ファーマシューティカルズ， インコーポレイテッド 癌の治療のための（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸を使用する方法
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
AU2006287149B2 (en) * 2005-09-02 2013-05-23 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
KR20080045279A (ko) * 2005-09-14 2008-05-22 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제 저해제로서의5-옥소-5,8-디하이드로-피리도-피리미딘
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
CA2654876A1 (en) * 2006-06-12 2007-12-21 Sunesis Pharmaceuticals, Inc. 1-8-naphthyridine compounds for the treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
ES2556677T3 (es) 2006-08-02 2016-01-19 Sunesis Pharmaceuticals, Inc. Utilización combinada de ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico y citarabina (Ara-C) para el tratamiento de la leucemia
AU2008317400B2 (en) * 2007-10-22 2014-10-02 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy
EP2249831A2 (en) * 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR101765956B1 (ko) 2008-12-31 2017-08-07 선에시스 파마슈티컬스 인코포레이티드 (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
CN104688732A (zh) 2009-02-27 2015-06-10 逊尼希思制药公司 利用sns-595治疗具有降低的brca2活性的癌症对象的方法
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
WO2011056566A2 (en) * 2009-10-26 2011-05-12 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
HRP20161786T1 (hr) 2011-05-13 2017-03-10 Array Biopharma, Inc. Pirolidinil urea, pirolidinil tiourea i pirolidinil gvanidin spojevi kao inhibitori trka kinaze
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
AU2018238079B2 (en) * 2017-03-24 2022-03-03 Wakunaga Pharmaceutical Co., Ltd. Novel pyridone carboxylic acid derivative or salt thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
JPS63500518A (ja) * 1985-06-13 1988-02-25 シェリング・コ−ポレ−ション 多環式キノリン、ナフチリジンおよびピラジノピリジン誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
EP0154780B1 (en) * 1984-01-26 1990-04-11 Abbott Laboratories Quinoline antibacterial compounds
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
US4851425A (en) * 1985-06-14 1989-07-25 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63500518A (ja) * 1985-06-13 1988-02-25 シェリング・コ−ポレ−ション 多環式キノリン、ナフチリジンおよびピラジノピリジン誘導体
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩

Also Published As

Publication number Publication date
NO965305D0 (no) 1996-12-11
WO1995034559A1 (en) 1995-12-21
EP0787726A1 (en) 1997-08-06
BR9508037A (pt) 1997-09-16
RO117793B1 (ro) 2002-07-30
ES2163512T3 (es) 2002-02-01
CA2192824C (en) 2006-11-07
DK0787726T3 (da) 2002-02-11
CZ364396A3 (en) 1997-06-11
MX9606331A (es) 1997-03-29
EP0787726B1 (en) 2001-11-28
FI965020A7 (fi) 1996-12-16
PL317726A1 (en) 1997-04-28
EP0787726A4 (enExample) 1997-08-06
CA2192824A1 (en) 1995-12-21
CZ292631B6 (cs) 2003-11-12
PT787726E (pt) 2002-04-29
PL181867B1 (pl) 2001-09-28
AU2576795A (en) 1996-01-05
JP3391796B2 (ja) 2003-03-31
AU679859B2 (en) 1997-07-10
KR100350921B1 (ko) 2002-11-18
DE69524251D1 (de) 2002-01-10
SK157496A3 (en) 1997-08-06
NO307255B1 (no) 2000-03-06
HUT75777A (en) 1997-05-28
ATE209645T1 (de) 2001-12-15
NO965305L (no) 1997-02-04
NZ287139A (en) 1997-07-27
HK1000495A1 (en) 2002-07-19
HU220072B (hu) 2001-10-28
HU9603455D0 (en) 1997-02-28
TW319769B (enExample) 1997-11-11
FI965020A0 (fi) 1996-12-13
CN1158614A (zh) 1997-09-03
RU2151770C1 (ru) 2000-06-27
FI112485B (fi) 2003-12-15
DE69524251T2 (de) 2002-07-11
US5817669A (en) 1998-10-06
SI0787726T1 (en) 2002-04-30
SK281341B6 (sk) 2001-02-12

Similar Documents

Publication Publication Date Title
CN1053668C (zh) 新型化合物及其制法和抗肿瘤剂
CN1178938C (zh) 1,2-稠合的喹啉衍生物
CN1165535C (zh) 抑制胃酸分泌的咪唑并吡啶衍生物
CN1310915C (zh) 作为DPP－IV抑制剂的吡啶并(2,1－a)异喹啉衍生物
CN1105715C (zh) 新型吡啶酮羧酸衍生物或其盐以及以它们为有效成分的抗菌剂
CN1161341C (zh) cGMP磷酸二酯酶的稠合吡啶并哒嗪抑制剂
CN1950371A (zh) 用作组胺h3受体配体的四氢萘啶衍生物
CN1805748A (zh) 作为raf激酶抑制剂的2－氨基嘧啶衍生物
CN1034724A (zh) 水溶性喜树碱类似物
CN1332742A (zh) 环氧噻酮衍生物及其作为抗肿瘤药的用途
CN1055182A (zh) N-(吡咯并《2，3-d》嘧啶-3-基酰基)-谷氨酸衍生物
CN1649871A (zh) 杂芳基取代的2－吡啶基和2－嘧啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮衍生物
CN1095068A (zh) 二环胺衍生物
CN1098103A (zh) 新型吡啶酮羧酸衍生物
CN1105720C (zh) 咪唑并哒嗪类化合物
CN1934082A (zh) 有机化合物
CN1227254C (zh) 吡啶酮化合物及其制备方法
CN1642954A (zh) 用作hiv逆转录酶抑制剂的三环型2－嘧啶酮化合物
CN1758910A (zh) 异喹啉衍生物治疗癌症和map激酶相关疾病的用途
CN1242011A (zh) 三环胺衍生物
CN1031941C (zh) 氟代乙基喜树碱衍生物的制备方法
CN1079744A (zh) 7-氧代-7H-吡啶并[1，2，3，-d，e][1，4]苯并嗪-6-羧酸及其酯
CN1234711C (zh) 薇甘菊内酯衍生物,其制备方法及其治疗用途
CN1284781C (zh) 具有抗肿瘤活性的多环化合物
CN1297556C (zh) 苯并[b]色烯并－萘啶－7－酮和吡喃并[2＇,3＇:7,8]喹啉并[2,3－b]喹喔啉－7－酮化合物、其制备方法及药用组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NIPPO SUMITOMO PHARMACEUTICALS CO., LTD.

Free format text: FORMER NAME OR ADDRESS: DAINIPPON PHARMACEUTICAL CO., LTD.

CP03 Change of name, title or address

Address after: Osaka City, Osaka of Japan

Patentee after: Dainippon Sumitomo Pharma Co., Ltd.

Address before: Osaka Japan

Patentee before: Dainippon Pharmaceutical Co., Ltd.

C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20150606

Granted publication date: 20000621